INVENTIVA ADS/1 O.N. (6IVA) - Total Liabilities
Based on the latest financial reports, INVENTIVA ADS/1 O.N. (6IVA) has total liabilities worth €278.03 Million EUR (≈ $325.05 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 6IVA operating cash flow to assess how effectively this company generates cash.
INVENTIVA ADS/1 O.N. - Total Liabilities Trend (2021–2025)
This chart illustrates how INVENTIVA ADS/1 O.N.'s total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of INVENTIVA ADS/1 O.N. to evaluate the company's liquid asset resilience ratio.
INVENTIVA ADS/1 O.N. Competitors by Total Liabilities
The table below lists competitors of INVENTIVA ADS/1 O.N. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Berliner Effektengesellschaft AG
F:BFV
|
Germany | €314.25 Million |
|
LuxExperience B.V.
NYSE:LUXE
|
USA | $953.76 Million |
|
Shanghai Haohai Biological Tech Co
SHG:688366
|
China | CN¥1.23 Billion |
|
Sweetgreen Inc
NYSE:SG
|
USA | $431.47 Million |
|
Rezolve AI Limited Ordinary Shares
NASDAQ:RZLV
|
USA | $364.92 Million |
|
Jupiter Life Line Hospitals Limited
NSE:JLHL
|
India | Rs5.72 Billion |
|
Lampsa Hellenic Hotels S.A
AT:LAMPS
|
Greece | €150.18 Million |
|
Cangzhou Dahua Co Ltd
SHG:600230
|
China | CN¥1.68 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down INVENTIVA ADS/1 O.N.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see INVENTIVA ADS/1 O.N. (6IVA) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -9.75 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how INVENTIVA ADS/1 O.N.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for INVENTIVA ADS/1 O.N. (2021–2025)
The table below shows the annual total liabilities of INVENTIVA ADS/1 O.N. from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €278.03 Million ≈ $325.05 Million |
+23.23% |
| 2024-12-31 | €225.61 Million ≈ $263.77 Million |
+122.08% |
| 2023-12-31 | €101.59 Million ≈ $118.77 Million |
+44.04% |
| 2022-12-31 | €70.53 Million ≈ $82.45 Million |
+112.96% |
| 2021-12-31 | €33.12 Million ≈ $38.72 Million |
-- |
About INVENTIVA ADS/1 O.N.
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat … Read more